ApoAI Western Ready Control
Cayman Chemical Item Number 10009751
Apolipoprotein AI
ApoAI Western Ready Control
Description
Application(s):
positive control for WB
·
Source:
human recombinant protein
·
Mr:
28 kDa
·
ApoAI is a major protein component in high-density lipoproteins (HDL). It acts as an acceptor for sequential transfers of phospholipids and free cholesterol from peripheral tissues and transports cholesterol to the liver and other tissues for excretion and steroidogenesis.1 Serum ApoAI levels are inversely related to the risk of developing atherosclerosis.2 Loss-of-function mutations in ApoAI are causes of diseases such as HDL deficiency type 1 (or Tangier disease) and type 2 (familial hypoalphalipoproteinemia), and systemic non-neuropathic amyloidosis. 3,4 Liver and small intestine are two main sources of the protein.
1
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
2
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
3
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
4
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
| Synonyms |
|
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
Wet ice
in continental US; may vary elsewhere
|
Background Reading
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
Show all 4
Hide all but first 3
|
Pricing updated 2012-02-10.
Prices are subject to change without notice.
To ask for assistance with one of our products please contact a Technical Support Scientist.
Warning This product is not for human or veterinary use.
Show all 5
Hide all but first 3
Downloads
Batch-specific Information
Login
to access batch-specific information
|
|
Cayman Chemical is a manufacturer, supplier and vendor of biochemical reagents, assay kits, antibodies, and proteins.
|